Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Olive

Showing results (1-10 of 276) with videos related to

Pageof 28
Sort By:
Bulletin Du Cancer|January 1, 2019
Daniel Olive
Medecine Sciences : M/S|December 13, 2006
[Lymphocyte coreceptors]Daniel Olive
F1000Research|June 4, 2020
Targeting the "PVR-TIGIT axis" with immune checkpoint therapiesLaurent Gorvel, Daniel Olive
Blood|June 7, 2014
AML drug resistance: c-Myc comes into playCyril Fauriat, Daniel Olive
Bulletin Du Cancer|August 30, 2008
[Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM]Christine Pasero, Daniel Olive
Advances in Experimental Medicine and Biology|October 29, 2020
γδ T Cells in Tumor MicroenvironmentCaroline Imbert, Daniel Olive
Medecine Sciences : M/S|July 3, 2003
[Can one separate GVH and GVT after allogenic hematopoietic stem cell transplantation?]Mohamad Mohty, Daniel Olive
Seminars in Immunology|December 2, 2022
Tumor associated macrophage in HPV<sup>+</sup> tumors: Between immunosuppression and inflammationLaurent Gorvel, Daniel Olive
Immunology Letters|February 27, 2013
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunityChristine Pasero, Daniel Olive
Cellular Immunology|October 4, 2005
T-cell: section reportArmand Bensussan, Daniel Olive
Pageof 28

Showing results (1-10 of 276) with videos related to

Sort By:
Pageof 28
Bulletin Du Cancer|January 1, 2019
Daniel Olive
Medecine Sciences : M/S|December 13, 2006
[Lymphocyte coreceptors]Daniel Olive
F1000Research|June 4, 2020
Targeting the "PVR-TIGIT axis" with immune checkpoint therapiesLaurent Gorvel, Daniel Olive
Blood|June 7, 2014
AML drug resistance: c-Myc comes into playCyril Fauriat, Daniel Olive
Bulletin Du Cancer|August 30, 2008
[Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM]Christine Pasero, Daniel Olive
Advances in Experimental Medicine and Biology|October 29, 2020
γδ T Cells in Tumor MicroenvironmentCaroline Imbert, Daniel Olive
Medecine Sciences : M/S|July 3, 2003
[Can one separate GVH and GVT after allogenic hematopoietic stem cell transplantation?]Mohamad Mohty, Daniel Olive
Seminars in Immunology|December 2, 2022
Tumor associated macrophage in HPV<sup>+</sup> tumors: Between immunosuppression and inflammationLaurent Gorvel, Daniel Olive
Immunology Letters|February 27, 2013
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunityChristine Pasero, Daniel Olive
Cellular Immunology|October 4, 2005
T-cell: section reportArmand Bensussan, Daniel Olive
Pageof 28